The FDA’s advisory panel recommends Moderna’s COVID-19 vaccine for children between the ages of 6 and 17
Check out what’s clicking on FoxBusiness.com.
An advisory committee to the FDA recommended Moderna’s COVID-19 vaccine for emergency use approval in children between 6 and 17 years of age on Tuesday by unanimous vote.
The FDA, which usually follows the committee’s advice, will probably give final approval to Moderna’s vaccine in this age group soon.
Pfizer’s COVID-19 vaccine was approved for teenagers a year ago and was approved for children between the ages of 5 and 1[ads1]1 last autumn, but the vaccination rate in these groups is still after the adult population.
A pharmacist has a vial of the Moderna COVID-19 vaccine in West Haven, Connecticut, USA, February 17, 2021. (REUTERS / Mike Segar / File Photo / Reuters)
About three-fifths of children between the ages of 12 and 17 are fully vaccinated, while only about one-third of children between the ages of 5 and 11 are fully vaccinated, according to CDC data.
COVID BOOSTER VACCINE CANDIDATE RAISES ANTIBODY RESPONSE TO OMICRON: MODERN
Nevertheless, some members of the Advisory Committee on Vaccines and Related Biological Products were hopeful that the approval of Moderna’s vaccine would provide families with more options.
“I want to give parents as many choices as possible, and let them make the decisions about this for their children,” said Dr. Arthur Reingold, a committee member and head of epidemiology at the University of California, Berkeley, at meeting Tuesday.
A healthcare professional administers a dose of a Modern COVID-19 vaccine at a vaccination clinic at the Norristown Public Health Center in Norristown, PA, on Tuesday, December 7, 2021. (AP Photo / Matt Rourke / AP Newsroom)
Modern vaccine has been discontinued due to concerns that it may cause a higher incidence of myocarditis, or heart inflammation, than Pfizer’s vaccine among young men.
Tom Shimabukuro, a member of the CDC’s Covid-19 Vaccine Coordination Unit, told the advisory panel on Tuesday that “some evidence suggests that the risk of myocarditis and pericarditis may be higher after Moderna than after Pfizer-BioNTech,” but “the findings are not consistent. all US surveillance systems. ”
READ MORE ABOUT FOX BUSINESS BY CLICKING HERE
The same panel will meet on Wednesday to review Moderna’s vaccine for children between 6 months and 6 years.
Reuters contributed to this report.
